MONROVIA, Calif. , Dec. 5, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the Company has earned a $10
Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement Monrovia, CAOctober 12, 2010 Xencor, Inc. announced today that the Company received a milestone payment from Boehringer Ingelheim. The payment was triggered by the regulatory
MONROVIA, Calif. , April 10, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the company has received a
Xencor Receives Milestone Payment from Pfizer Under Antibody Technology License Agreement Monrovia, CADecember 16, 2009 Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today that the Company received a milestone
Xencor Receives Patent for its Proprietary Antibody Fc Optimization Technology Monrovia, Calif. – January 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, announced today that it received a patent from the United States Patent and Trademark Office (US 7,317,091 B1)
Xencor Receives SBIR Phase II Grant for High Throughput Screening of Novel Computationally Derived Optimized Proteins (BW Healthwire)–June 19, 2001—Paves the Way for Improved Biopharmaceuticals and New Industrial and Agricultural Products Xencor today announced that the company has been awarded a
Xencor Receives Second Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement MONROVIA, Calif., April 4, 2012 Xencor, Inc. announced today that the Company received a milestone payment under a technology license agreement with Boehringer Ingelheim.
Xencor Receives Two Patents For Ultra-Fast Optimization Technology To Create A New Generation Of Biotechnology Products Xencor Receives Two Patents For Ultra-Fast Optimization Technology To Create A New Generation Of Biotechnology Products (BW Healthwire)–August 06, 2001—Protein Design Automation™
-- Initial data from the ongoing Phase 1 study in patients with B-cell malignancies expected in 2019 -- -- Xencor and Novartis to continue co-developing XmAb®14045, a CD123 x CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia -- MONROVIA, Calif. , Jan.